Difference between revisions of "Cholangiocarcinoma - historical"
Jump to navigation
Jump to search
(Created page with "<span id="BackToTop"></span> <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px;...") |
Warner-admin (talk | contribs) m (Text replacement - "'''contains dosing details in manuscript'''" to "'''dosing details in manuscript have been reviewed'''") |
||
| Line 37: | Line 37: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | #Rao S, Cunningham D, Hawkins RE, Hill ME, Smith D, Daniel F, Ross PJ, Oates J, Norman AR. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer. 2005 May 9;92(9):1650-4. [https://doi.org/10.1038/sj.bjc.6602576 link to original article] ''' | + | #Rao S, Cunningham D, Hawkins RE, Hill ME, Smith D, Daniel F, Ross PJ, Oates J, Norman AR. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer. 2005 May 9;92(9):1650-4. [https://doi.org/10.1038/sj.bjc.6602576 link to original article] '''dosing details in manuscript have been reviewed''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362051/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/15856037/ PubMed] |
==FELV {{#subobject:ut11a8|Regimen=1}}== | ==FELV {{#subobject:ut11a8|Regimen=1}}== | ||
FELV: '''<u>F</u>'''luorouracil , '''<u>E</u>'''toposide & '''<u>L</u>'''euco'''<u>V</u>'''orin (Folinic acid) | FELV: '''<u>F</u>'''luorouracil , '''<u>E</u>'''toposide & '''<u>L</u>'''euco'''<u>V</u>'''orin (Folinic acid) | ||
| Line 64: | Line 64: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | #Rao S, Cunningham D, Hawkins RE, Hill ME, Smith D, Daniel F, Ross PJ, Oates J, Norman AR. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer. 2005 May 9;92(9):1650-4. [https://doi.org/10.1038/sj.bjc.6602576 link to original article] ''' | + | #Rao S, Cunningham D, Hawkins RE, Hill ME, Smith D, Daniel F, Ross PJ, Oates J, Norman AR. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer. 2005 May 9;92(9):1650-4. [https://doi.org/10.1038/sj.bjc.6602576 link to original article] '''dosing details in manuscript have been reviewed''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362051/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/15856037/ PubMed] |
[[Category:Cholangiocarcinoma regimens]] | [[Category:Cholangiocarcinoma regimens]] | ||
Revision as of 11:48, 15 July 2024
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main cholangiocarcinoma page for current regimens.
2 regimens on this page
2 variants on this page
|
Metastatic, first-line therapy
ECF
ECF: Epirubicin, Cisplatin, Fluorouracil
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Rao et al. 2005 | 1997-2003 | Phase 3 (E-switch-ic) | FELV | Did not meet primary endpoint of OS |
Chemotherapy
- Epirubicin (Ellence) 50 mg/m2 IV once on day 1
- Cisplatin (Platinol) 60 mg/m2 IV once on day 1
- Fluorouracil (5-FU) 200 mg/m2/day IV continuous infusion over 21 days, started on day 1 (total dose per cycle: 4200 mg/m2)
21-day cycles
References
- Rao S, Cunningham D, Hawkins RE, Hill ME, Smith D, Daniel F, Ross PJ, Oates J, Norman AR. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer. 2005 May 9;92(9):1650-4. link to original article dosing details in manuscript have been reviewed link to PMC article PubMed
FELV
FELV: Fluorouracil , Etoposide & LeucoVorin (Folinic acid)
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Rao et al. 2005 | 1997-2003 | Phase 3 (C) | ECF | Did not meet primary endpoint of OS |
Chemotherapy
- Fluorouracil (5-FU) 600 mg/m2 IV bolus once per day on days 1 to 3, given first
- Etoposide (Vepesid) 120 mg/m2 IV over 40 minutes once per day on days 1 to 3, given second
- Leucovorin (Folinic acid) 60 mg/m2 IV bolus once per day on days 1 to 3, given third
21-day cycles
References
- Rao S, Cunningham D, Hawkins RE, Hill ME, Smith D, Daniel F, Ross PJ, Oates J, Norman AR. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer. 2005 May 9;92(9):1650-4. link to original article dosing details in manuscript have been reviewed link to PMC article PubMed